Connect
← Return to PRRT has been approved by the FDA Jan 26, 2018, as expected
Discussion
PRRT has been approved by the FDA Jan 26, 2018, as expected
Neuroendocrine Tumors (NETs) | Last Active: Feb 11, 2023 | Replies (15)Comment receiving replies
My wife Lynn as a low level of expression of somatostatin receptors. Dr. Halfdanarson had Mayo pathologists call back the slides and stain for somatostatin receptor type 2A to see how much of the receptor truly is present on the tumor cells. It turns out that its does not meet the minimum threshold for PRRT. Therefore he started her on Afinitor in March 2018.
Replies to "My wife Lynn as a low level of expression of somatostatin receptors. Dr. Halfdanarson had Mayo..."
Connect
Tom:
My wife is scheduled to begin PRRT on 3/9/2023 @ Fred Hutch - Seattle. The oncologist, after a recent Ga68 C/T scan, recommended this therapy. She has not been evaluated for receptor type 2A presence.
We understand each patient is unique - just want some general guidance.
1. After reading your post, my question is out of ignorance - in any case, should we request that the type 2A amount be checked?
2. What is the minimum threshold?
3. Is Afinitor still used?
Many thanks,
Mark